Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.81 |
| ▸ | BTK | Q06187 | 5/20 | 0.81 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.75 |
| ▸ | ULK1 | O75385 | 1/20 | 0.67 |
| ▸ | SYK | P43405 | 2/20 | 0.58 |
| ▸ | ITK | Q08881 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12519471 | 0.90 | EGFR (1.00) | EGFRBTKPTK2ULK1MAPK3 | |
| SCHEMBL29722434 | 0.90 | EGFR (1.00) | EGFRBTKPTK2ULK1MAPK3 | |
| SCHEMBL12518481 | 0.88 | EGFR (0.80) | EGFRBTKPTK2ULK1SYK | |
| SCHEMBL29722500 | 0.85 | EGFR (1.00) | EGFRBTKPTK2ITKMAPK3 | |
| SCHEMBL12519518 | 0.85 | EGFR (1.00) | EGFRBTKPTK2ITKMAPK3 | |
| SCHEMBL21443532 | 0.83 | PTK2 (0.77) | EGFRBTKPTK2ULK1SYK | |
| SCHEMBL12518708 | 0.83 | EGFR (0.87) | EGFRBTKPTK2ULK1 | |
| SCHEMBL29722381 | 0.83 | EGFR (1.00) | EGFRBTKPTK2ITKMAPK3 | |
| SCHEMBL12519451 | 0.83 | EGFR (1.00) | EGFRBTKPTK2ITKMAPK3 | |
| SCHEMBL11916368 | 0.82 | PTK2 (0.62) | EGFRBTKPTK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | EGFR 460/4885BTK 261/4885PTK2 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.